Fundraising FoxGalaxy Therapeutics
Milpitas, US · Founded 2020 · Delaware corporation
Find your way into Galaxy Therapeutics
Sign up to see every warm intro you have to Galaxy Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Galaxy Therapeutics team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Galaxy Therapeutics is a clinical-phase medical device company developing the SEAL Embolization Device, an intrasaccular flow diversion implant for treating brain aneurysms. Its products target neurointerventional physicians and are progressing through FDA PMA and European CE Mark regulatory pathways.
Founders & leadership
Reported raises · per SEC filings
Form D private placements$13M disclosed across 4 rounds · 2020–2022
▶$7.6MraisedJul 2024 · 50 investors · Other Health CareRule 506(b)
▶$7.6MraisedJul 2024 · 50 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Osama ZaidatExecutive Officer, Director
- Amount sold
- $7.6M
- First sale
- Aug 2022
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$2.1MraisedJul 2024 · 26 investors · Other Health CareRule 506(b)
▶$2.1MraisedJul 2024 · 26 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Osama ZaidatExecutive Officer, Director
- Amount sold
- $2.1M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$3MraisedJul 2024 · 47 investors · Other Health CareRule 506(b)
▶$3MraisedJul 2024 · 47 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Osama ZaidatExecutive Officer, Director
- Amount sold
- $3M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$325KraisedFeb 2020 · 3 investors · Other Health CareRule 506(b)
▶$325KraisedFeb 2020 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- OSAMA ZAIDATExecutive Officer, Director
- AAMIR BADRUDDINExecutive Officer, Director
- EDGARD PEREIRAExecutive Officer, Director
- THOMAS WOLFEExecutive Officer, Director
- Amount sold
- $325K
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Galaxy Therapeutics.
Frequently asked questions
- What does Galaxy Therapeutics do?
- Galaxy Therapeutics is a clinical-phase medical device company developing the SEAL Embolization Device, an intrasaccular flow diversion implant for treating brain aneurysms. Its products target neurointerventional physicians and are progressing through FDA PMA and European CE Mark regulatory pathways.
- How much funding has Galaxy Therapeutics raised?
- Galaxy Therapeutics has disclosed $13M raised across 4 rounds.
- Where is Galaxy Therapeutics headquartered?
- Galaxy Therapeutics is headquartered in Milpitas, US.